- Home
- PHAR vs MSEX Comparison
PHAR vs MSEX Comparison
Compare PHAR & MSEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- MSEX
- Stock Information
- Founded
- PHAR 1988
- MSEX 1897
- Country
- PHAR Netherlands
- MSEX United States
- Employees
- PHAR N/A
- MSEX N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- MSEX Water Supply
- Sector
- PHAR Health Care
- MSEX Utilities
- Exchange
- PHAR Nasdaq
- MSEX Nasdaq
- Market Cap
- PHAR 1.0B
- MSEX 933.6M
- IPO Year
- PHAR N/A
- MSEX N/A
- Fundamental
- Price
- PHAR $14.60
- MSEX $53.42
- Analyst Decision
- PHAR Strong Buy
- MSEX Buy
- Analyst Count
- PHAR 3
- MSEX 4
- Target Price
- PHAR $30.00
- MSEX $61.00
- AVG Volume (30 Days)
- PHAR 11.5K
- MSEX 126.5K
- Earning Date
- PHAR 10-23-2025
- MSEX 10-30-2025
- Dividend Yield
- PHAR N/A
- MSEX 2.55%
- EPS Growth
- PHAR N/A
- MSEX 17.05
- EPS
- PHAR N/A
- MSEX 2.41
- Revenue
- PHAR $339,836,000.00
- MSEX $195,831,000.00
- Revenue This Year
- PHAR $16.63
- MSEX $5.46
- Revenue Next Year
- PHAR $6.77
- MSEX $8.74
- P/E Ratio
- PHAR N/A
- MSEX $22.11
- Revenue Growth
- PHAR 22.44
- MSEX 11.91
- 52 Week Low
- PHAR $7.06
- MSEX $48.18
- 52 Week High
- PHAR $17.08
- MSEX $70.73
- Technical
- Relative Strength Index (RSI)
- PHAR 57.37
- MSEX 50.16
- Support Level
- PHAR $13.51
- MSEX $52.30
- Resistance Level
- PHAR $15.61
- MSEX $54.08
- Average True Range (ATR)
- PHAR 0.87
- MSEX 1.08
- MACD
- PHAR -0.06
- MSEX 0.04
- Stochastic Oscillator
- PHAR 59.37
- MSEX 66.02
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About MSEX Middlesex Water Company
Middlesex Water Co owns and operates regulated water utility and wastewater systems in the U.S. The firm operates in the eastern states of New Jersey, Delaware, and Pennsylvania. The company has two operating segments, Regulated and Non-Regulated. The regulated business includes collecting and distributing water to residential, commercial, industrial, and fire protection consumers. The non-regulated business includes contract services for the operation of private water and wastewater systems. The majority of the company's revenue is derived from the Regulated segment and from residential customers.